博暉創新(300318.SZ):董事長翟曉楓窗口期誤買入2.9萬股
格隆匯 1 月 26日丨博暉創新(300318.SZ)公佈,公司董事會於近日收到公司董事長翟曉楓的通知,翟曉楓於2021年1月25日買入公司股票2.9萬股,買入均價11.20元,成交金額32.48萬元。
經核查,上述股票交易因翟曉楓操作失誤導致,雖然在公司披露業績預吿的敏感期內發生,但不存在因獲悉內幕信息而交易公司股票的情況。截止本公吿日,翟曉楓持有公司股票32.7811萬股,佔公司總股本比例0.04%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.